Clinical trials blocking BAFF in MS warranted by animal models also decreased antibody titres (12) but failed in terms of treatment outcome in MS, where B cell subset shifts appear more important (12, 13, 38). This evidence concerns the gene TNFSF13B and myeloid sarcoma.